Novo Nordisk CEO eyes "huge opportunity" in unused capacity at Catalent
On Monday, Novo Nordisk announced a billion-dollar acquisition of three factories from US-based Catalent, which among other things produces the Danish company’s GLP-1 product, but also the competing product from Elli Lilly.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.